Patents by Inventor Tilman Schlothauer

Tilman Schlothauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160151487
    Abstract: The invention provides anti-IGF-1R antibodies with abolished FcRn-binding and methods of using the same for the treatment of vascular eye diseases.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • Publication number: 20160068613
    Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the fi
    Type: Application
    Filed: April 25, 2014
    Publication date: March 10, 2016
    Inventors: Joerg Thomas REGULA, Wolfgang SCHAEFER, Tilman SCHLOTHAUER
  • Publication number: 20150239981
    Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
    Type: Application
    Filed: January 22, 2015
    Publication date: August 27, 2015
    Applicant: Roche Glycart AG
    Inventors: Monika BAEHNER, Stefan JENEWEIN, Manfred KUBBIES, Ekkehard MOESSNER, Tilman SCHLOTHAUER
  • Publication number: 20150140683
    Abstract: Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 21, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Petra Rueger, Tilman Schlothauer, Stefan Seeber
  • Patent number: 8969526
    Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: March 3, 2015
    Assignee: Roche Glycart AG
    Inventors: Monika Baehner, Stefan Jenewein, Manfred Kubbies, Ekkehard Moessner, Tilman Schlothauer
  • Publication number: 20150018241
    Abstract: Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody.
    Type: Application
    Filed: February 14, 2013
    Publication date: January 15, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberto Falkenstein, Hubert Hertenberger, Petra Rueger, Tilman Schlothauer
  • Publication number: 20120251531
    Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
    Type: Application
    Filed: March 27, 2012
    Publication date: October 4, 2012
    Inventors: Monika Baehner, Stefan Jenewein, Manfred Kubbies, Ekkehard Moessner, Tilman Schlothauer
  • Publication number: 20110183354
    Abstract: The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.
    Type: Application
    Filed: March 1, 2011
    Publication date: July 28, 2011
    Inventors: ULRICH BRINKMANN, PETER BRUENKER, CLAUDIA FERRARA KOLLER, MARTIN LANZENDOERFER, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, ANNE ZECK
  • Publication number: 20110045510
    Abstract: The current invention reports an immunoassay for the determination of PEGylated insulin-like-growth-factor employing an anti-(polyethylene glycol) antibody and an anti-digoxygenin antibody for the detection of an insulin-like-growth-factor/insulin-like-growth-factor-binding-protein-complex.
    Type: Application
    Filed: March 31, 2009
    Publication date: February 24, 2011
    Inventors: Kurt Lang, Andreas Schaubmar, Julia Schleypen, Tilman Schlothauer
  • Publication number: 20080248510
    Abstract: The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 9, 2008
    Inventors: Ulrich Brinkmann, Peter Bruenker, Claudia Ferrara Koller, Martin Lanzendoerfer, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Anne Zeck